The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO GI 2024 | The emerging role of checkpoint inhibitors in liver cancer
Stephen Chan, MBBS, MRCP, The Chinese University of Hong Kong, Hong Kong, China, comments on advances in the management of liver cancer. Current targeted therapies have failed to produce durable responses and have associated toxicities. Immune checkpoint inhibitors have demonstrated to be superior to tyrosine kinase inhibitors (TKIs) alone. This interview took place at 2024 European Society for Medical Oncology (ESMO) Gastrointestinal Cancers Annual Congress in Munich, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
I think for the past ten years there have been a revolutionary changes in the systemic therapy for liver cancer. Ten years ago, we are still using the targeted agents as the mainstay of treatment for liver cancer. Although we do see improvement of survival, but usually the responses are not durable. And also the patient will suffer a lot of the TKI related toxicity, like the skin rash, diarrhea or hypertension...
I think for the past ten years there have been a revolutionary changes in the systemic therapy for liver cancer. Ten years ago, we are still using the targeted agents as the mainstay of treatment for liver cancer. Although we do see improvement of survival, but usually the responses are not durable. And also the patient will suffer a lot of the TKI related toxicity, like the skin rash, diarrhea or hypertension. Uh, Over the past five years, there have been a lot of studies on the use of the immune checkpoint inhibitors on the liver cancer. And nowadays we know that the regimen based on the combination with these immunotherapy, there’s a relatively high response rate than the use of TKI alone. And more importantly, there have been improvement of the overall survival. And also, when we look at the tail of the survival curve, there’s a lot of patients who have a durable response and live longer. And for example, there’s recently some studies showing that at the time of four years of time, around 15 to 20% of patients could survive at that time, even with advanced disease. I consider this a very important for our patients.
Read more...
Disclosures
Honoraria – AstraZeneca; Eisai; Ipsen; Roche
Consulting or Advisory Role – AstraZeneca; BMS; Eisai; MSD Oncology; Roche
Research Funding – Eisai; Ipsen
